trending Market Intelligence /marketintelligence/en/news-insights/trending/b97N2AQQv0GLkdoGltviGw2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Gemphire stock falls as cholesterol drug disappoints in phase 2b trial

Blog

JMP Securities is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

M&A rebound sparks optimism for near-term deal activity

Blog

Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

Banking Essentials Newsletter - February Edition


Gemphire stock falls as cholesterol drug disappoints in phase 2b trial

Gemphire Therapeutics Inc.'s cholesterol drug, gemcabene, met its primary endpoint in a phase 2b study but failed to match results observed in previous trials.

Under the Royal-1 trial, gemcabene was seen to significantly decrease low-density lipoprotein cholesterol, or LDL-C, in hypercholesterolemic patients: 17.2% versus 5.5% for placebo, but still lower than what was observed previously.

The trial enrolled 56 females and 49 males with a mean age of 61.

Gemphire Therapeutics shares were down nearly 47% to $9.93 at market close on Aug. 7.